Long term follow-up of the gimema GSI 103 AMLE randomized trial: Daunoxome seems to improve disease-free survival (DFS) of elderly patients with acute myelogenous leukemia (AML).

R. LATAGLIATA;M. BRECCIA;S. IACOBELLI;P. FAZI;G. MARTINELLI;DI RAIMONDO, FRANCESCO;M. SBORGIA;F. FABBIANO;F. LAURIA;E. ZUFFA;A. VENDITTI;M. CRUGNOLA;A. PETA;A. CANDONI;D. CILLONI;E. MATTEI;M. MORSELLI;D. PASTORE;F. ADAMO;A. CENTRA;F. FALZETTI;M. VIGNETTI;G. ALIMENA;AND F. MANDELLI

2006-01-01